https://www.selleckchem.com/products/2-d08.html Loss of efficacy (LOE) is a well-known phenomenon associated with spinal cord stimulation (SCS) and is the leading cause of explant. Although recent advances in neuromodulation have resulted in a decreased incidence of LOE, it still occurs. Intuition suggests that when LOE ensues, switching to a different SCS therapy/platform could potentially be a viable clinical option; however, there are no data presently available to validate this theory. The primary objective was to evaluate the efficacy of SCS therapy rotation with DeRidder Burst on reversing LOE. A subobjective was to evaluate the hypothesis that the body will treat a novel waveform as a "different therapy" when introduced for the first time, regardless of the setting. Multicenter, retrospective. Private practice. A total of 307 patients with ongoing SCS therapy had a de novo therapy conversion to DeRidder Burst via surgical revision or software upgrade. Each cohort was split into 2 additional arms/subcohorts those who were failing their SCS stimulation may be an effective option for treating LOE, as well as potentially reducing opioid consumption, regardless of the prior SCS system. LOE is an unfortunate occurrence with few evidence-based solutions presently available to reverse it. Our findings suggest that implementing D-Burst stimulation may be an effective option for treating LOE, as well as potentially reducing opioid consumption, regardless of the prior SCS system. Percutaneous vertebroplasty is a minimally invasive technique to treat patients with symptomatic vertebral hermangiomata. We present a single-operator series of cases to demonstrate the clinical outcomes and complication profiles for this technique. This is a retrospective multi-center cohort study. Procedures were performed across multiple hospitals in Italy by a single proceduralist. All patients with symptomatic vertebral hermangiomata that had percutaneous vertebroplasty over a 14-year peri